Rohit Thummalapalli

@rohit_thum

GI medical oncologist @MSKCancerCenter focused on neuroendocrine and hepatobiliary cancers. Prior @oslerresidency @harvardmed @yale. Views my own.

New York, NY Joined July 2010

566 Following 769 Followers 1.1K Posts

Latest posts 5

Rohit Thummalapalli @rohit_thum 5d

Second player in this space - excited for most recent update for zoci (DLL3 ADC) phase 1b/2 program: 40% RR, mDOR 5.6 mo in chemorefractory pts, activity seen in DLL3-low/negative pts as well. Frontline cohort now open, phase 3 designs being discussed. #NANETS2026

Rohit Thummalapalli @rohit_thum 5d

@AmanChauhanMD presents very promising update for DAREON-7 (upfront chemotherapy + obrixtamig) - RR 77%, mDOR 12.5 mo, mPFS 7.7 mo (9.5 mo in DLL3-high). Phase 3 DAREON-NEC-1 underway…. #NANETS2026

Rohit Thummalapalli @rohit_thum Oct 24

Amazing data that we can only hope to replicate in epNEC…#ESMO26

Anirban Maitra @Aiims1742 Oct 24

From #ESMO26 & @NEJM
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
nejm.org/doi/full/10.10…
Practice changing data for a terrible disease with hazard ratios that are unequivocal.
View quoted post on X

Rohit Thummalapalli @rohit_thum Jun 2

Remarkable consistency across trials that >50% DLL3 expression is required for TCE monotherapy activity in NECs. How to evoke responses in lower expressors is our next challenge (?combinations, ADCs, others…). #ASCO26

Angela Lamarca @DrAngelaLamarca Jun 2

ZG006- Phase II trial with trispecific T Cell Engager DLL3/DLL3/CD3 in NEC at @ASCO #ASCO26

ORR if DLL3 high at 30 mg 56%, DOR 11.7 months

🙌🏻Consistent - DLL3 works in NEC

View quoted post on X

Rohit Thummalapalli @rohit_thum May 31

It’s out! Congratulations @EileenMOReilly and we are thrilled offer daraxonrasib to our patients soon - access can’t come soon enough! @MSK_DeptOfMed @MSKCancerCenter #ASCO26

chadi nabhan MD, MBA, FACP Verified account @chadinabhan May 31

Remarkable results for patients with pancreatic cancer now published in @NEJM - congrats to @EileenMOReilly @DrShubhamPant @MiteshBorad and co-authors for leading one of the most transformative trials in this disease. @RevMedicines @ASCO #ASCO26

nejm.org/doi/full/10.10…
View quoted post on X